Filing Details

Accession Number:
0001140361-22-034012
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-09-20 16:30:42
Reporting Period:
2022-09-16
Accepted Time:
2022-09-20 16:30:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1802768 Royalty Pharma Plc RPRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1814882 Germano Mario Giuliani C/O Gisev Family Office Sa
Contrada Di Sassello 2
Lugano V8 6900
No No No No
1814889 Strategic Mgg - S.a. Sif Sicaf Strategic Mgg 18 Avenue De La Porte Neuve
Luxembourg N4 L-2227
No No No No
1922189 S.a. Sif Sicaf Strategic Mgg 18 Avenue De La Porte Neuve
Luxembourg N4 L-2227
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Ordinary Shares Disposition 2022-09-16 154,986 $41.72 22,890,000 No 4 S Indirect See Footnotes
Class A Ordinary Shares Disposition 2022-09-19 232,185 $41.50 22,657,815 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Ordinary Shares 8,577,140 Indirect See Footnotes
Class A Ordinary Shares 50,000 Indirect See Footnotes
Class A Ordinary Shares 3,477,520 Indirect See Footnotes
Footnotes
  1. Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.
  2. Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.
  3. Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.
  4. Reflects securities held by the spouse of M. Germano Giuliani.
  5. Reflects securities held directly by Avara Management Ltd.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.325 to $42.06 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.995 to $41.79 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.